Health and health care disparities are pervasive across the spectrum of kidney disease.
1
Kidney failure disproportionately affects Black and Hispanic persons, those with low
socioeconomic status, and homeless and housing insecure individuals.2, 3, 4, 5 The
etiology of these disparities stems from complex interrelationships between social
disadvantage, medical comorbidities, genetic factors, and historical/structural racism.
In the context of the disproportionate impact of coronavirus disease 2019 (COVID-19)
on Black and Hispanic communities,
6
its bidirectional association with kidney disease,
7
,
8
and heightened awareness of racial injustices in this country, correcting health disparities
in kidney disease is all the more crucial.
On June 3, 2020, the Centers for Medicare and Medicaid Services (CMS) Innovation Center
announced COVID-19 related adjustments to two kidney-focused alternative payment models
(APMs): 1) an extension of ESRD Seamless Care Organizations (ESCOs) until March 31,
2021, and 2) the establishment of the Kidney Care Choices (KCC) Model starting in
April 2021 with a deferral option.
9
This promising news reflects a national commitment to redesign kidney care and achieve
the goals of the Advancing American Kidney Health (AAKH) Executive Order. Notably,
however, a discussion surrounding kidney health disparities has been largely absent
in federal communications surrounding AAKH. While other policy-level interventions
such as Medicaid Expansion may be effective in reducing disparities, the current role
of APMs to address disparities remains limited.
10
Moving forward, it is imperative that new payment models and care delivery strategies
be thoughtfully and intentionally designed to address disparities in kidney care.
This editorial outlines current knowledge and proposed solutions such that APMs can
mitigate rather than potentiate disparities in kidney care.
Potential Impact of APMs on Disparities in Kidney Disease
APMs are reimbursement mechanisms that reward clinicians and health systems for high-quality,
cost-efficient care. APMs often incorporate financial incentives and penalties, and
have shown to reduce costs across a variety of settings.
11
,
12
Nephrology has long been an early adopter of APMs, including the ESRD Prospective
Payment System (PPS), ESRD Quality Incentive Program (QIP), and ESCOs, which involve
differing levels of financial risk sharing, moving away from solely fee-for-service
driven care (Figure 1
). Within the new voluntary Kidney Care Choices model, the Kidney Care First option
introduces capitated payments for nephrology clinicians while the Comprehensive Kidney
Care Contracting (CKCC) options incorporate shared savings and losses, offering a
high level of financial risk sharing and the greatest potential for flexibility in
care delivery.
Figure 1
Kidney disease alternative payment models and level of risk sharing. Reproduced in
modified form from Mann et al
30
with permission of the copyright holder (The Commonwealth Fund).
APMs can serve to reduce disparities if resources are targeted towards disadvantaged
populations, or if these populations differentially benefit from care delivery interventions.
For example, Accountable Care Organizations, one of CMS’s largest APMs, may have reduced
certain disparities for surgical care related to spinal fractures.
13
Thus far, the impact of APMs on kidney care disparities has been understudied. One
analysis found that differences in erythropoietin doses or laboratory values between
Black and non-Black patients did not widen or narrow between August 2010 and December
2011, after bundled payments in the ESRD PPS were implemented.
14
Independent dialysis facilities serving fewer patients with employer-based insurance
had a higher prevalence of hemoglobin levels <10 g/dL under the ESRD PPS, compared
with independent facilities with more commercially insured patients, providing evidence
that bundled payments may have contributed to socioeconomic disparities in anemia
management.
15
In the ESRD QIP, dialysis facilities serving higher proportions of patients with dual-eligibility
status, Black race, and lower neighborhood-level income had lower quality scores and
were more likely to be penalized.
16
,
17
While lower QIP scores are associated with higher mortality,
18
the impact of the QIP program itself on disparities in care or health outcomes for
patients on dialysis is unclear. Regarding ESCOs, these ACOs were associated with
fewer hospitalizations and less catheter usage,
19
and ESCO-aligned patients were more likely to be Black.
20
Black participants in ESCOs had significant reductions in costs and increases in fistula
usage compared with those in matched comparison facilities, whereas white participants
did not have significant changes in costs or fistula usage.
21
Taken together, the findings of these initial studies are mixed, and do not yet suggest
an overall conclusion of the impact of APMs on kidney care disparities.
The Role of Disparities-Sensitive Quality Measures in APMs
The new Kidney Care Choices Model incentivizes performance on quality measures related
to patient activation, depression remission, hypertension control, and vascular access.
22
Other measures are under development, including a standardized mortality ratio and
a measure of delayed progression to kidney failure. As a first step to better understand
disparities in care delivery, quality measures in Kidney Care Choices and other APMs
should be stratified by race/ethnicity and socioeconomic status, as recommended by
the National Quality Forum.
23
Using these “disparities-sensitive measures” can allow health systems and CMS to monitor
relative and absolute health disparities over time, more appropriately target care
management resources, and ensure that care delivery interventions do not exacerbate
disparities. Kidney Care Choices and other APMs could test strategies for rewarding
improvement on quality measures, including closing disparities.
Accounting for Social Risk Factors In APMs
APMs measure the quality and cost of care using risk adjustment to account for differences
in patient populations. Risk adjustment for CMS programs traditionally uses Hierarchical
Condition Categories which account for patient comorbidities but do not incorporate
social risk factors, which are defined as adverse social conditions associated with
poor health, such as low socioeconomic position, being in a disadvantaged racial/ethnic
group, lack of social relationships, and adverse residential and community context.
24
Social risk factors are highly prevalent among patients with kidney disease and are
associated with adverse outcomes.
1
Not accounting for social risk factors results in higher penalties to nephrology practices
and dialysis facilities that serve disadvantaged populations, who typically score
less well on quality measures. Thus, designing socially-informed payment models is
critical to ensure that APMs do not have unintended consequences of exacerbating disparities
in kidney disease.
However, there is also concern that adjusting for social risk factors would mask and
institutionalize disparities, and currently there is an active debate whether APMs
should adjust for social risk factors. Thus, future research should evaluate different
approaches to incorporate social risk factors in new kidney APMs. For example, the
proposed ESRD Treatment Choices (ETC) Model would incentivize home dialysis rates,
which would result in greater penalties to dialysis facilities serving a higher proportion
of homeless or housing insecure, Black or Hispanic, and low socioeconomic status patients.
25
Not adjusting for social risk factors may incentivize dialysis facilities to preferentially
select patients who are likely to be candidates for home dialysis and transplant.
Additionally, further research should evaluate which quality measures should be adjusted
for social risk factors, as some measures may be less influenced by patient social
factors.
16
Universal Social Determinants of Health Assessments in Dialysis Facilities
In order for social factors to be incorporated in kidney APMs, payment models could
rely on the limited social determinants found in claims data, or collect more granular
individual-level social determinants, which are currently not being systematically
captured. Social determinants— the environmental determinants or conditions into which
people are born, grow, live, work and age— have a substantial impact on health-related
outcomes. A myriad of social determinants are associated with limited health care
access, low health status, and poor health outcomes.
26
Kidney disease quality of care is highly influenced by social determinants and social
needs. There are now structured tools to screen for social needs, including the Accountable
Health Communities (AHC) Health-Related Social Needs (HRSN) Screening Tool, recently
developed by CMS in conjunction with the National Academy of Medicine.
27
The AHC HRSN is a 10-item self-administered tool assessing 5 core domains (housing
instability, food insecurity, transportation problems, utility help needs, and interpersonal
safety), in addition to 8 supplemental domains.
We propose that universal social needs screening be implemented and studied in dialysis
facilities with the AHC HRSN or other tools.
28
Dialysis facilities may be highly feasible sites to collect individual-level social
needs using existing staff and resources, given the high frequency of patient visits
and embedded multidisciplinary care teams. Much of this data is already collected
by social workers in dialysis facilities, but the use of a structured assessment tool
has two key advantages. First, a systematic approach would ensure that unmet social
needs are universally collected and intervened upon as part of medical care. For example,
connecting housing insecure individuals to community resources for permanent housing
may facilitate greater home dialysis uptake, in line with AAKH goals. Second, screening
tools would capture this information in structured data formats, facilitating research
and information sharing in the electronic health record. Ultimately, existing CROWNWeb
infrastructure could be used to report social factors to CMS for potential performance
and payment adjustment. Future research would estimate the additional staff time and
costs associated with social needs collection and reporting, and the optimal frequency
of collection, which could start with yearly.
In summary, amidst longstanding disparities in kidney care, APMs carry the potential
to mitigate these disparities and should be immediately leveraged for this purpose.
Disparities-sensitive quality measures, social risk factor adjustment, and universal
social needs screening are potential solutions that should be further evaluated in
new voluntary and mandatory payment models in AAKH. It is critical that APMs and other
policies and care delivery interventions work to promote health equity,
23
shifting towards third- and fourth-generation disparities research that provides solutions
to eliminate disparities.
29